7 active not recruiting, 2 completed. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 7, Completed 2 |
Follow Refractory Ependymoma: new trials by email Literature Review of Refractory Ependymoma trials Research Report on Refractory Ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
Ependymoma (9) · Glioma (9) · Hepatoblastoma (9) · Histiocytosis, Langerhans-Cell (9) · Lymphoma, Non-Hodgkin (9) · Medulloblastoma (9) · Neuroblastoma (9) · Neuroectodermal Tumors, Primitive, Peripheral (9) · Rhabdoid Tumor (9) · Wilms Tumor (9) · Osteosarcoma (8) · Rhabdomyosarcoma (8) · Sarcoma (8) · Sarcoma, Ewing (5) · Central Nervous System Neoplasms (4)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genetic Diseases, Inborn (9) · Hemic and Lymphatic Diseases (9) · Histiocytosis (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Kidney Diseases (9) · Kidney Neoplasms (9) · Lung Diseases (9) · Lung Diseases, Interstitial (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Male Urogenital Diseases (9)
Magnetic Resonance Spectroscopy (4) · Nuclear Medicine Department, Hospital (4) · Phantoms, Imaging (4) · X-Rays (4) · Biopsy (3) · Specimen Handling (3) · Pharmacogenomic Variants (1) · ensartinib (1) · erdafitinib (1) · ivosidenib (1) · larotrectinib (1) · olaparib (1) · palbociclib (1) · selpercatinib (1) · tipifarnib (1)
National Cancer Institute (NCI) (9)
Puerto Rico (9) · United States (9) · Australia (3) · Canada (1)
Alice Lee (1) · Andrea T Franson (1) · Christine A Pratilas (1) · Elizabeth D Alva (1) · Julia Glade-Bender (1) · Katherine A Janeway (1) · Kieuhoa T Vo (1) · Meredith S Irwin (1) · Rajen Mody (1)
PMID 31401903, PMID 34486544, PMID 38815151, PMID 38935895, PMID 39298716, PMID 42853672, PMID 42867148
U10CA180886 (9), UM1CA081457 (1)